Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | BCL6 | P41182 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7914638 | 0.77 | PTK2 (0.40) | MLYCDSMN1; SMN2ALDH1A1 | |
| SCHEMBL209580 | 0.75 | KDM4C (0.42) | MLYCDSMN1; SMN2ALDH1A1 | |
| SCHEMBL15378494 | 0.69 | MLYCD (0.47) | MLYCDSMN1; SMN2ALDH1A1HDAC3HDAC1 | |
| SCHEMBL28393110 | 0.67 | HRH4 (0.40) | MLYCD | |
| SCHEMBL20567991 | 0.67 | FSCN1 (0.40) | SMN1; SMN2BCL6ALDH1A1HDAC3HDAC1 | |
| SCHEMBL24260284 | 0.66 | FSCN1 (0.33) | MLYCDALDH1A1 | |
| SCHEMBL26763994 | 0.66 | LIPE (0.50) | ALDH1A1 | |
| SCHEMBL18935755 | 0.65 | MLYCD (0.50) | MLYCDALDH1A1 | |
| SCHEMBL16418854 | 0.65 | SYK (0.39) | ALDH1A1 | |
| SCHEMBL19987474 | 0.64 | RAB9A (0.39) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299185-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2015-10-22 | — | — | US | disclosed |
| EP-2797909-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | Hanmi Pharm. Co., Ltd. (KR) | 2014-11-05 | — | — | EP | disclosed |
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013100631-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
| US-6214801-B1 | INHIBITION OF DNA OR RNA VIRAL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2001-04-10 | — | — | US | disclosed |
| WO-1997027205-A1 | IMIDAZO[1,2-A]PYRIDINE C-NUCLEOSIDES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299185-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | LCK, ABL1, TYK2 | MLYCD 2377/4885SMN1; SMN2 3730/4885BCL6 1552/4885 |
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | MLYCD 3331/4885SMN1; SMN2 3132/4885BCL6 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.